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Abstract
Background: Lysozyme is an antimicrobial innate immune molecule degrading peptidoglycan of
the bacterial cell wall. Lysozyme shows the ubiquitous expression in wide varieties of species and
tissues including the tubotympanum of mammals. We aim to investigate the effects of lysozyme
depletion on pneumococcal clearance from the middle ear cavity.
Methods: Immunohistochemistry was performed to localize lysozyme in the Eustachian tube.
Lysozyme expression was compared between the wild type and the lysozyme M-/- mice using real
time quantitative RT-PCR and western blotting. Muramidase activity and bactericidal activity of
lysozyme was measured using a lysoplate radial diffusion assay and a liquid broth assay, respectively.
To determine if depletion of lysozyme M increases a susceptibility to pneumococal otitis media, 50
CFU of S. pneumoniae 6B were transtympanically inoculated to the middle ear and viable bacteria
were counted at day 3 and 7 with clinical grading of middle ear inflammation.
Results: Immunolabeling revealed that localization of lysozyme M and lysozyme P is specific to
some/particular cell types of the Eustachian tube. Lysozyme P of lysozyme M-/- mice was mainly
expressed in the submucosal gland but not in the tubal epithelium. Although lysozyme M-/- mice
showed compensatory up-regulation of lysozyme P, lysozyme M depletion resulted in a decrease
in both muramidase and antimicrobial activities. Deficiency in lysozyme M led to an increased
susceptibility to middle ear infection with S. pneumoniae 6B and resulted in severe middle ear
inflammation, compared to wild type mice.
Conclusion: The results suggest that lysozyme M plays an important role in protecting the middle
ear from invading pathogens, particularly in the early phase. We suggest a possibility of the
exogenous lysozyme as an adjuvant therapeutic agent for otitis media, but further studies are
necessary.
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Otitis media (OM), or middle ear infection is one of the
most common pediatric infectious diseases, second only
to the common cold and the most common cause of hear-
ing impairment in children [1,2]. It is not a life-threaten-
ing disease, but its socioeconomic impact is significant
[3]. The rapid worldwide increase of antibiotic resistance
among OM pathogens such as S. pneumoniae and non-
tyepable H. influenzae has given rise to an urgent need to
develop new non-antibiotic approaches to prevent and
manage this disease [4].
OM occurs when OM pathogens of the nasopharynx enter
the middle ear via the Eustachian tube (E-tube) [5]. E-tube
is covered by mucociliary epithelium as a part of the upper
respiratory tract, connecting the middle ear cavity to the
nasopharynx. It plays an important role in the ventilation
and protection of the middle ear cavity [6]. Under certain
circumstances, when these microorganisms colonize
nasopharyngeal mucosal surface as commensal bacteria,
they may gain access to the middle ear cavity through the
E-tube, resulting in OM [7,8]. Defense of the E-tube and
middle ear (tubotympanum) against invading pathogens
is provided by numerous factors including the mucocili-
ary system and the antimicrobial molecules of the innate
and adaptive immune systems [9].
Lysozyme, extensively studied as one of the antimicrobial
innate immune molecules (AIIMs), is ubiquitously syn-
thesized and secreted by glandular serous cells, surface
epithelial cells, and macrophages in the human airway
[10-12]. In the tubotympanum, lysozyme is found in spe-
cialized epithelial cells, including those of the serous
glands of the E-tube and middle ear mucosa [9,13]. Mice
have two lysozyme genes [14]: 1) lysozyme M predomi-
nantly expressed in macrophage, bone marrow and lung
tissue, and 2) lysozyme P mainly expressed at high levels
in the small intestine (Paneth cells) and at much lower or
undetectable levels in other cells/tissues. [15]. Only lys-
ozyme M gene targeted animals are available as a model
of lung and skin infection [16,17]. We aimed to assess the
muramidase activity and the antimicrobial property of
lysozyme in the E-tube of lysozyme M-/- mice in order to
evaluate the role of lysozyme in OM pathogenesis. In this
study, we show for the first time that depletion of lys-
ozyme results in delayed clearance of S. pneumoniae from
the middle ear cavity.
Methods
Bacterial culture
Streptococcus pneumoniae serotype 6B was purchased from
ATCC (Manassas, VA). The bacteria were plated on choc-
olate agar plate and incubated overnight at 37°C in 5%
CO2. A single colony was inoculated in 10 ml of Todd-
Hewitt broth (THB, Becton Dickinson, Cockeysville, MD)
and incubated overnight. One ml of this overnight culture
was then transferred to 9 ml of fresh medium and incu-
bated for a further 3 h. The bacteria were washed twice
with 10 mM sodium phosphate and the optical density
(O.D.) at 620 nm was determined after resuspension in
sterile saline.
Animals and the middle ear infection model
Lysozyme M-/- mice were generously provided by Dr.
Tomas Ganz (University of California, Los Angeles, CA).
Lysozyme M-deficient mice (in which green fluorescent
protein was knocked into the lysozyme M locus) were
generated as previously described [18]. Since the resulting
transgenic mice contained contributions from both
C57BL/6 and 129Sv strains the non-transgenic parental
strain C57BL/6 was chosen as a control mouse. All mice
were housed under SPF conditions and all aspects of ani-
mal handling were performed according to the approved
IACUC guidelines.
In total 56 eight-week old mice of C57BL/6 and lysozyme
M-/- mice were used in this study. Four mice were used for
immunolabeling, 12 mice for protein and RNA extraction,
and 40 mice for the infection study. Animals were anes-
thetized intraperitoneally, with a cocktail of 20 mg/ml of
ketamine-HCl and 2.5 mg/ml of xylazine. Similar to a pre-
viously described study [19], we determined the optimum
concentration of S. pneumoniae that causes substantial
middle ear inflammation without mortality in wild type
mice. The middle ear was transtympanically inoculated
with 50 CFU of S. pneumoniae 6B in 5 μl of sterile saline.
The tympanic membrane was observed on the 1st, 3rd, 5th
and 7th day after inoculation using an otoscopic digital
imaging system, MedRx VetScope System® (MedRx Inc.,
Largo, FL). Tympanic membrane inflammation was
graded on a scale of 0 to 2 as follows; Grade 0: normal,
Grade 1: mild inflammation with air-fluid level and
Grade 2: severe inflammation with massive middle ear
effusion. Middle ear lavage was collected on day 3 and day
7 by washing with 5 μl of sterile saline for four times and
was subsequently plated on chocolate agar plates. Colo-
nies were counted after overnight incubation. To confirm
the recovered bacteria, PCR was performed using the spe-




Immunolabeling was performed to assess the expression
profile of lysozyme in the mouse E-tube. 8-week-old lys-
ozyme M-/- and age-matched wild type mice were sacri-
ficed, and the temporal bones were removed and fixed in
4% paraformaldehyde in PBS. After decalcification in 125
mM EDTA in PBS for 2 weeks, the temporal bones were
dehydrated and embedded in paraffin. Six μm-thick sec-Page 2 of 11
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For antigen retrieval, pre-heated citrate buffer (0.01 M, pH
6.0) was applied for 15 min at 37°C. 3% hydrogen perox-
ide solution was applied for 10 min to block endogenous
peroxidase activity. After blocking with 10% non-immune
goat serum for 30 min, the sections were incubated with
1:1000 rabbit polyclonal anti-human lysozyme antibody
(EC 3.2.1.17) (DAKO, Carpinteria, CA) overnight at 4°C.
After washing three times with PBS, the biotinylated sec-
ondary antibody was applied for 30 min at room temper-
ature. After peroxidase was attached by the avidin/biotin
complex method, signals were detected by 3-amino-9-
ethylcarbazole (AEC) (Zymed Laboratories Inc., San Fran-
cisco, CA). For a negative control, the non-immune rabbit
serum was used. Sections were viewed and photographed
using a Zeiss Axiovert® 135 TV microscope equipped with
AxioVision® systems (Zeiss, Germany). To evaluate the
phenotypic expression of lysozyme at different parts of
the E-tube, lysozyme-positive cells of the tubal epithelium
were counted and normalized to the total number of non-
ciliated tubal epithelial cells since ciliated cells are lys-
ozyme negative. The lysozyme expression pattern was
shown by the ratio of the lysozyme-positive tubal epithe-
lial cells to the total non-ciliated tubal epithelial cells.
Real time quantitative PCR
Lung tissue and E-tube tissue were obtained from the wild
type and the lysozyme M-/- mice. Total RNA was isolated
using TRIzol® reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer's protocol. cDNA was generated
from 1 μg of total RNA using a Superscript II-kit (Gibco
BRL, Rockville, MD). Real time quantitative PCR was per-
formed to assess lysozyme M and lysozyme P mRNA
expression using 7500 Real Time PCR System (Applied
Biosystems, Atlanta, GA) with SYBR® Green PCR Master
Mix (Applied Biosystems) as described previously [21].
The primers used in this study are as follows: lysozyme M
(GenBank Accession No. AH001999): 5'-CTGGCTACTAT-
GGAGTCAGC-3' and 5'-TTGATCCCACAGGCATTCAC-3',
lysozyme P (GenBank Accession no. BC061129): 5'-CAG-
GCCAAGGTCTACAATCG-3' and 5'-TTGATCCCACAG-
GCATTCTT-3', and 18S rRNA (GenBank accession no.
V012705): 5'-GTGGAGCGATTTGTCTGGTT-3' and 5'-
CGCTGAGCCAGTCAG TGTAG-3'. Cycle threshold (CT)
values of lysozyme M and lysozyme P were normalized to
the mouse 18S rRNA internal control, and relative quan-
tity of mRNA was determined by the 2(-DDCT) method
[22]. Results were expressed as a fold-expression of mRNA
quantity, taking the value of the lysozyme P mRNA in the
lung as 1.
Lysoplate radial diffusion assay for muramidase activity
The mouse E-tube was dissected after euthanization with
CO2 inhalation. The tissue was weighed and homoge-
nized using a Pellet Pestle® Motor (Kontes Co., Vineland,
NJ) with 2 volumes (v/w) of 5% acetic acid. The extract
was centrifuged at 10,000 × g for 45 min and the superna-
tant was collected and stored at -80°C. Total protein con-
centration was measured using the Bio-Rad protein assay
kit (Bio-Rad, Hercules, CA). 0.5 mg/ml lyophilized Micro-
coccus lysodeiktikus (Sigma, St. Louis, MO) was suspended
in 66 mM sodium phosphate buffer (Na2HPO4/
NaH2PO4, pH 7.4) and poured into a square Petri dish
with 1% agarose in 66 mM sodium phosphate as
described previously [23]. 4 mm-sized wells were made
using a cork borer (WR Scientific, West Chester, PA), and
filled with 6 μl of either tissue homogenates (0.17 mg/ml)
or serial dilutions of chicken egg white lysozyme (Sigma)
as standards. After overnight incubation at room temper-
ature, the muramidase activity was determined by meas-
uring the diameter of the clear zone relative to the
standards.
Gel-overlay assay
The gel-overlay assay was performed to demonstrate the
activity of lysozyme fraction in the tissue homogenate as
previously described [24]. Briefly, the E-tube homogenate
was extracted with 5% acetic acid and vacuum-dried. After
resuspension in 3 × loading dye, the E-tube homogenate
(15 μg/lane) was separated on a 12.5% Acid-Urea polyacr-
ylamide gel electrophoresis (AU-PAGE) for 1.5 h at 100 V.
The gel was washed for 20 min in 10 mM sodium phos-
phate buffer pH 7.4 and placed on a pre-made underlay
gel (0.1 × THB, 10 mM sodium phosphate, 0.8% low elec-
troendosmosis (EEO)-type agarose) containing either 106
CFU/10 ml of S. pneumoniae (for antimicrobial activity) or
lyophilized M. lysodeiktikus (for muramidase activity).
After incubation of both over-lay and under-lay gels at
37°C for 3 h, the AU-PAGE (over-lay) gel was removed,
and the underlay gel was further incubated overnight at
37°C in a 5% CO2. After staining with Coomassie Blue,
the clear zones were visualized, showing antimicrobial
activity and muramidase activity of lysozyme fraction in
the tissue homogenate.
Liquid broth assay
Antimicrobial activity of the E-tube homogenate was
determined as described previously [25]. Briefly, one
tenth of an overnight culture broth was transferred to
fresh medium and allowed to grow to exponential phase.
After washing with phosphate-buffered saline, bacteria
were suspended in a standard assay buffer (1% THB
medium -10 mM sodium phosphate, pH 7.4) and O.D
was measured at 620 nm. 2.5 × 104 CFU/mL of S. pneumo-
niae was then exposed to the E-tube homogenate (100 μg/
mL) or lysozyme from human milk (Sigma) or chicken
egg white for 2 h at 37°C. Viability of S. pneumoniae was
measured by plating several dilutions to the chocolate
agar and counting the number of colonies after overnight
incubation at 37°C.Page 3 of 11
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The E-tube homogenate (15 μg/lane) was separated on a
12.5% Acid-Urea polyacrylamide gel electrophoresis (AU-
PAGE) for 1.5 h at 100 V. Then the gels were blotted to
PVDF membranes (Invitrogen, Carlsbad, CA) for 40 min
in 0.7% acetic acid and 10% methanol at 0.18 amperes.
After fixation with 10% formalin in TBS (Tris-buffered
saline), the membranes were blocked in 5% non-fat dry
milk in TBS for 1 h at room temperature. The membranes
were incubated with a 1:5,000 dilution of rabbit polyclo-
nal anti-human lysozyme antibody (EC 3.2.1.17)
(DAKO) overnight at 4°C. After washing with 1× TBST
(Tris-buffered saline with 0.05% Tween 20), the mem-
branes were incubated with a 1:3,000 dilution of HRP-
conjugated anti-rabbit IgG (Cell Signaling Technology,
Danvers, MA). After washing, the membranes were incu-
bated in SuperSignal substrate (Pierce Biotechnologies)
for 1 min at room temperature. The chemiluminescence
signal was detected by exposure to X-ray film and quanti-
tated using the Quantity One® software (Bio-Rad Labora-
tories, Hercules, CA).
Statistical Analysis
All experiments were carried out in triplicate. Results were
expressed as mean ± standard deviation. Statistical analy-
sis was performed using Student's t-test, with significance
considered to be p < 0.05. Fisher's exact test was particu-
larly performed for analyzing bacterial clearance and host
inflammation data between wild type and lysozyme M-/-
mice, with significance considered to be p < 0.05.
Results
Localization of lysozyme M and lysozyme P in the E-tube
We characterized the pattern of lysozyme expression in
the E-tube of wild type and lysozyme M-/- mice. Immu-
nolabeling was performed using the polyclonal anti-
human lysozyme antibody, recognizing both lysozyme M
and lysozyme P. Lysozyme was widely labeled in the tubal
epithelial cells and the submucosal glandular cells of the
wild type mice. There were distinct differences in the dis-
tribution of the lysozyme-positive cells along the length of
the E-tube. In the pharyngeal and the middle portions of
the wild type mouse E-tube, lysozyme-positive cells were
localized mainly in the inferior recessed portion of the
luminal surface (Figure 1B, C). In the tympanic orifice,
most epithelial cells showed a positive labeling with lys-
ozyme in wild type, but virtually none in lysozyme M-/-
mice (Figure 1D). The secretion was noted in the tubal
lumen of both mice with lysozyme-positive labeling only
in the wild type mice, but not in the lysozyme M-/- mice.
Interestingly, the E-tube of lysozyme M-/- mice showed
very few lysozyme-positive cells in the tubal epithelium
compared to the submucosal glands. This indicates that
lysozyme P isoform in lysozyme M-/- mice is predomi-
nantly expressed in the submucosal glands, and not in the
tubal epithelium.
To determine the distribution of lysozyme-positive cells
in the tubal epithelium, we counted total tubal epithelial
cells and lysozyme-positive cells from three regions – pha-
ryngeal orifice, middle portion and tympanic orifice – of
the E-tube (Table 1). There was no significant difference in
the distribution of the lysozyme-positive tubal epithelial
cells along the length of the E-tube in the wild type mice.
The lysozyme-positive tubal epithelial cells were signifi-
cantly decreased in lysozyme M-/- mice at all three por-
tions of the E-tube, compared to the wild type mice.
Lysozyme P in the E-tube of lysozyme M-/- mice
It is reported that lysozyme P is normally inactive in mac-
rophages, but knockout of the lysozyme M gene induces
lysozyme P expression [16]. To determine the compensa-
tory up-regulation of lysozyme P in the E-tube and the
lung of lysozyme M-/- mice, conventional RT-PCR was per-
formed. The results showed compensatory up-regulation
of lysozyme P when substituting lysozyme M gene with
EGFP in lysozyme M-/- mice (Figure 2A). We then per-
formed real time quantitative PCR to measure the relative
quantity of lysozyme M and lysozyme P mRNA. Taking
the value of the lysozyme P mRNA of the lung as 1, lys-
ozyme P mRNA was remarkably up-regulated in the E-
tube of lysozyme M-/- mice, compared to the lung (Figure
2B). In the lysozyme M-/- mice, lysozyme P mRNA of the
E-tube was unexpectedly up-regulated more than 6
folded, compared to that of the lung.
We sought to explore the lysozyme protein expression in
the E-tube. The soluble protein fraction of the E-tube
homogenate was separated using 12.5% AU-PAGE elec-
trophoresis and subsequently transferred onto PVDF
membranes and labeled with a polyclonal anti-human
lysozyme antibody (1:5000), recognizing both lysozyme
M and lysozyme P proteins. As shown in Figure 2C and
2D, the western blot and its densitometry demonstrated
that lysozyme M protein is depleted and lysozyme P pro-
tein is up-regulated in the E-tube of lysozyme M-/- mice,
compared to wild type mice.
Muramidase activity and antimicrobial activity of 
lysozyme M-/- mice
To examine the muramidase activity of the E-tube
homogenate, the lysoplate radial diffusion assay was per-
formed, which contained lyophilized Micrococcus lysodeik-
tikus, a substrate of muramidase. The E-tube homogenate
of lysozyme M-/- mice showed depletion of muramidase
activity (Figure 3A). The muramidase activity of the tissue
homogenate (1 μg) was converted to that of a chicken egg
white lysozyme as a standard (Figure 3B). Interestingly,
the E-tube homogenate contained higher amount of lys-Page 4 of 11
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homogenate. Moreover, the gel-overlay assay with the lys-
oplate gel showed that the E-Tube homogenate of the lys-
ozyme M-/- mice lacks muramidase activity at the
corresponding level of lysozyme (Figure 3C).
To examine the antimicrobial activity of tissue homoge-
nates, the liquid broth assay was performed. 2.5 × 104
CFU/mL of S. pneumoniae 6B was incubated with the puri-
fied lysozyme and the E-tube homogenate (100 μg/mL)
for 2 hours at 37°C. Human and chicken lysozyme
showed antimicrobial activity of against S. pneumoniae in
Immunolabeling showing the phenotypic expression of lysozyme in the E-tubeFigure 1
Immunolabeling showing the phenotypic expression of lysozyme in the E-tube. The schematic illustration showing 
right tympanic bulla and E-tube of a mouse (A). ME: middle ear, ET: Eustachian tube, NP: nasopharynx, TM: tympanic mem-
brane, PO: pharyngeal orifice, TO: tympanic orifice, C: tubal cartilage, TL: E-tube lumen. Cross-sections at level b, c and d of 
both wild type and lysozyme M-/- mice are shown in B, C and D. Lysozyme is labeled in both the submucosal gland (SG) and the 
E-tube epithelium (arrow heads) of wild type mice while it is labeled predominantly in the submucosal gland (SG) of lysozyme 
M-/- mice. This indicates that lysozyme P of lysozyme M-/- mice is predominantly expressed in the submucosal gland, not in the 
tubal epithelium, considering that the polyclonal antibody recognizes both lysozyme M and lysozyme P. The secretion in the 
tubal lumen (arrow) is also immunolabeled with lysozyme in wild type mice, but not in lysozyme M-/- mice. All sections were 
immunolabeled with anti-human lysozyme antibody (1:1,000) and counterstained with hematoxylin. For each pair of images the 
left-hand panel displays sections from wild type mice and the right-hand displays sections from lysozyme M-/-mice. TC: tubal 
cartilage, TL: E-tube lumen. SG: submucosal gland. Original magnification: × 100.
Table 1: Distribution of lysozyme-positive cells in the E-tube epithelium.
Distribution of lysozyme-positive cells (%)*
Mouse Pharyngeal orifice Middle portion Tympanic orifice
Wild type 37.8 ± 22.0 39.0 ± 5.8 45.4 ± 2.5
Lysozyme M-/- 0 2.6 ± 2.3 0.5 ± 0.9
(p < 0.05) (p < 0.01) (p < 0.01)
*: The number of lysozyme-positive cells was divided by total number of non-ciliated epithelial cells. Values are given as the mean ± standard 
deviation (n = 3).Page 5 of 11
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was inactivated by 94% when incubated with the wild
type E-tube homogenate (Figure 3E). In contrast, only
46% of S. pneumoniae 6B was inactivated, when incubated
with the lysozyme M-/- E-tube homogenate (p < 0.01). The
gel-overlay assay with the bacterial lawn of S. pneumoniae
6B demonstrated antimicrobial activity of the E-tube
homogenate decreased in the lysozyme M-/- mice at the
corresponding level of lysozyme (Figure 3F).
Susceptibility to S. pneumoniae-induced OM of lysozyme 
M-/- mice
To determine if lysozyme M deficiency increases suscepti-
bility to pneumococcal middle ear infection, live S. pneu-
moniae 6B was transtympanically inoculated to the mouse
middle ear. After otoscopic observation and photography
of the tympanic membrane, the middle ear lavage was
plated on chocolate agar plates and colonies were counted
after overnight incubation at 37°C in 5% CO2 in order to
quantify live bacteria. Within one day after inoculation,
most of the mice began to show inflammation, character-
ized by a small amount of turbid and yellow fluid in the
Compensatory up-regulation of lysozyme P in lysozyme M-/- miceFigur  2
Compensatory up-regulation of lysozyme P in lysozyme M-/- mice. Conventional RT-PCR shows compensatory up-
regulation of lysozyme P when substituting the lysozyme M gene with EGFP in lysozyme M-/- mice (A). Real time quantitative 
RT-PCR analysis shows that lysozyme P is remarkably up-regulated in the E-tube of lysozyme M-/- mice, compared to the lung 
(B). ND: not detected. Results were expressed as a fold-expression of mRNA quantity, taking the value of lysozyme P mRNA 
of the lung as 1. Values are given as mean ± standard deviation. n = 3. *: p < 0.05. The western blot (C) and its densitometry 
(D) show the expression of lysozyme protein in the E-tube homogenate. As expected, lysozyme M protein (arrow) is depleted 
and lysozyme P protein (arrow head) is up-regulated in the E-tube of lysozyme M-/- mice, compared to wild type mice. The sol-
uble protein fraction of the E-tube homogenate was separated using 12.5% AU-PAGE electrophoresis, subsequently trans-
ferred onto PVDF membranes and labeled with a polyclonal anti-lysozyme antibody (1:5000). Signal was detected by exposure 
to X-ray film and quantified by the Quantity One® software.Page 6 of 11
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clearance from the middle ear of lysozyme M-/- mice was
significantly delayed on day 3, but not on day 7 (Table 2).
On day 3, eight out of 9 lysozyme M-/- mice showed posi-
tive bacterial culture on day 3, but none of 10 wild type
mice. In contrast, only one out of 10 lysozyme M-/- mice
showed positive bacterial culture on day 7, but none of 9
wild type mice. The otoscopic findings (Figure 4A)
showed that the middle ear inflammation is severe one
day after inoculation of live S. pneumoniae 6B in lysozyme
M-/- mice, compared to the wild type mice (Figure 4B). On
day 1, Grade 0 (no inflammation) was seen in 13 (68.4%)
out of 19 wild type mice, but only 4 (21.1%) out of 19 lys-
ozyme M-/- mice. Grade 2 (severe inflammation with
abundant effusion) was not seen in wild type mice, but 7
(36.8%) out of 19 in lysozyme M-/- mice. However, the
later clinical courses (on day 3, 5 and 7) were not different
between wild type and lysozyme M-/- mice. Taken together
with bacterial clearance data, this indicates that lysozyme
M plays an important protective role at the early phase of
infection.
Discussion
In this study, we demonstrated that lysozyme M defi-
ciency results in a decrease in both muramidase activity
and antimicrobial property of E-tube in spite of compen-
satory up-regulation of lysozyme P.
Moreover, we showed for the first time that lysozyme M-/-
mice were more susceptible to pneumococcal OM with
severe inflammation compared to wild type mice, espe-
cially in the early phase. It was hardly expected that lys-
ozyme M deficiency resulted in delayed clearance of S.
Depletion of muramidase activity and antimicrobial activity to S. pneumoniae 6B in the E-tube homogenate of lysozyme M-/- miceFigure 3
Depletion of muramidase activity and antimicrobial activity to S. pneumoniae 6B in the E-tube homogenate of 
lysozyme M-/- mice. The lysoplate radial assay of the E-tube homogenate shows depletion of muramidase activity in lysozyme 
M-/- mice (A). The lysoplate was containing lyophilized Micrococcus lysodeiktikus, a substrate of muramidase. The muramidase 
activity of the tissue homogenate (1 μg) is expressed relative to that of a chicken egg white lysozyme as a standard (B). The gel-
overlay assays with the lysoplate demonstrate that the E-tube homogemate of lysozyme M-/- mice lacks muramidase activity 
(arrow) at the corresponding level of lysozyme (C). The liquid broth assay shows antimicrobial activity of human and chicken 
lysozyme against S. pneumoniae in a dose-dependent manner (D). Antimicrobial activity of the E-tube homogenate decreases in 
lysozyme M-/- mice, compared to wild type mice (E). 2.5 × 104 CFU/mL of S. pneumoniae 6B were incubated with or without the 
E-tube homogenate (100 μg/mL) for 2 hours at 37°C. Con: the vehicle control, incubated without the E-tube homogenate. Val-
ues are given as mean ± standard deviation. All experiments were triplicated. *: p < 0.05, **: p < 0.01. The gel-overlay assays 
with the bacterial lawn of S. pneumoniae 6B demonstrate that antimicrobial activity of the E-tube homogenate (arrow) is 
decreased in the lysozyme M-/- mice compared to the wild type mice (F).Page 7 of 11
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just one of the anitimicrobial molecules.
Our result suggests that lysozyme M plays a critical role as
a major antimicrobial molecule of the E-tube against S.
pneumoniae before induction of host adaptive immune
system. Experiments are currently underway with over-
expressing lysozyme M mice to see if these transgenic mice
are more resistant to infection.
Although introduction of antibiotics has led to a decrease
in the incidence of life-threatening complications of OM
[26], the rapid emergence of antibiotic resistant OM path-
ogens requires an alternative strategy for management of
OM [27]. AIIMs are considered as a possible alternative
therapeutic approach, which could overcome current
trends of increasing antibiotic resistance among OM path-
ogens. There are evidences demonstrating bacterial coun-
termeasures to AIIMs, such as covalent modification of
bacterial wall and/or membrane and expression of mem-
brane proteases destroying AIIMs [28-31]. However, it is
likely that bacteria have not generally developed effective
resistance to AIIMs, considering AIIMs have been around
for a long time in the animal kingdom.
Lysozyme is highly expressed in the tubotympanum of all
the species examined, such as guinea pigs, chinchillas,
rats, and mice [9] and increases with age in both humans
[32] and in mice [33]. It is also present in the middle ear
effusion of OM patients although at higher concentra-
tions in the mucoid effusion compared to the serous effu-
sion [34,35]. The presence of lysozyme in serous cells of
Depletion of lysozyme M affects the course of middle ear inflammationFigure 4
Depletion of lysozyme M affects the course of middle ear inflammation. The illustration of the mouse tympanic 
membrane and the otoscopic views show clinical grades (0, 1 and 2) of the middle ear inflammation (A). OS: ossicles. TM: tym-
panic membrane. *: the epitympanic space with air-fluid level. White arrow heads: middle ear effusions. The otoscopic findings 
show that the middle ear inflammation is severe at 1 day after inoculation of live S. pneumoniae 6B in lysozyme M-/- mice, com-
pared to wild type mice (B). However, the later clinical courses are not different between wild type and lysozyme M-/- mice. 
This indicates that lysozyme M plays an important role at the early phase of infection, corresponding with the bacterial clear-
ance result (see Table 2). N: number of animals. **: Fisher Exact Test, p < 0.01.Page 8 of 11
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a role for this molecule in the defense of the middle ear
and E-tube against pathogens[9,32,34].
Lysozyme is a 14 kD cationic enzyme, hydrolyzing the β
(1–4) glycosidic bond between the two major repeating
components of peptidoglycan: N-acetyl muramic acid and
N-acetyl glucosamine [36]. Although there is a debate
about the mechanism of lysozyme's antimicrobial activity
such as muramidase-dependent and -independent mech-
anisms [37,38], it is believed that the muramidase activity
of lysozyme plays a critical role in inducing inflammation
of hosts by production of peptidoglycan fragments [39].
For the muramidase-independent antimicrobial mecha-
nism, it is known that the cationic helix-loop-helix struc-
ture of lysozyme is important [40].
In mammals, lysozyme can be found in most tissues and
is an important component of the innate defense system
of all mucosal surfaces, including the digestive tract, geni-
tourinary tract, the respiratory tract, as well as the E-tube
and the middle ear [9-12]. Lysozyme over-expression
leads to an increased survival rate after streptococcal and
pseudomonal lung infection [41], while lysozyme defi-
ciency results in a decrease in pseudomonal clearance
from the airways [17] and an increase in micrococcal skin
inflammation [16]. Consistent with these findings, our
result also showed that lysozyme deficiency results in an
increased susceptibility to pneumococcal OM in mice.
In mice, there are two types of lysozyme: lysozyme M and
lysozyme P as mentioned earlier. The 130-amino-acid
mature peptides of both lysozyme M and lysozyme P dif-
fer by only 11 amino acid substitutions [16], which results
in differences in electrophoretic migration and antimicro-
bial activity. Lysozyme M and lysozyme P show similar
bactericidal activity against Gram-positive bacteria,
whereas lysozyme M is more effective than lysozyme P in
killing Gram-negative bacteria [42]. We here focused on
lysozyme M because it is a predicted orthologue of human
lysozyme. We previously demonstrated that human lys-
ozyme reduces the viability of a major OM pathogen such
as S. pneumoniae 6B in a dose-dependent manner and acts
synergistically with β defensin-2 [43], another very impor-
tant member of AIIMs. Lysozyme alone is not very effec-
tive against Gram-negative bacteria, while lysozyme, in
combination with lactoferrin and defensin is bactericidal
against several Gram-negative strains such as Haemophilus
influenzae [9,44].
Lysozyme P is normally inactive in macrophages, but lys-
ozyme M gene deletion results in a compensatory increase
of lysozyme P expression [16,42]. The disruption of the
lysozyme M gene may alter the DNA conformation at the
locus, resulting in aberrant transcription of genes from
regions that are downstream of the lysozyme M locus,
some of which are regulatory [45]. However, further stud-
ies are necessary to elucidate the underlying molecular
mechanisms. Our results showed that lysozyme P is up-
regulated in the E-tube of lysozyme M-/- mice, compensat-
ing lysozyme M depletion, but it apparently seems to be
insufficient for protection. We demonstrated up-regula-
tion of lysozyme P mRNA in the lysozyme M-/- mice, but
lysozyme P protein activity (muramidase or antimicrobial
activity) was not apparent in the protein concentration
range (< 0.2 mg/ml), used in this study. Moreover, lys-
ozyme was labeled only in the submucosal glands of the
lysozyme M-/- mice, indicating predominant expression of
lysozyme P in the submucosal glands, not in the tubal epi-
thelium. It is suggested that lysozyme M and lysozyme P
are differentially expressed, specific to some non-ciliated
epithelial cell types of the E-tube, but further study is nec-
essary. Finally our result showed that lysozyme M-inde-
pendent muramidase or antimicrobial activity was
Table 2: Bacterial clearance from the middle ear.
Post-inoculation day Positive Bacterial Culture*
Wild type Lysozyme M-/- Fisher's Exact Test
3 0/10 1+: 0 8/9 1+: 2 p < 0.01
2+: 0 2+: 3
3+: 0 3+: 2
4+: 0 4+: 1
7 0/9 1+: 0 1/10 1+: 1 NS
2+: 0 2+: 0
3+: 0 3+: 0
4+: 0 4+: 0
*: The middle ear lavage was collected at 3 and 7 days after inoculation of live bacteria to investigate the presence of live bacteria. Values are given 
as the number of culture positive animals/total number of animals. NS: no significant difference. 1+: 1 ~ 10 colonies, 2+: 11 ~ 20 colonies, 3+: 21 ~ 
30 colonies, 4+: > 30 colonies.Page 9 of 11
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BMC Infectious Diseases 2008, 8:134 http://www.biomedcentral.com/1471-2334/8/134insufficient for compensate lysozyme M deficiency, sug-
gesting lysozyme M is most abundant in the basal, non-
stimulated state compared to other AIIMs, which are usu-
ally inducible upon exposure to pro-inflammatory stimu-
lation.
Conclusion
Taken together, it is evident that lysozyme M plays a criti-
cal role in protecting the middle ear against invading
pathogens, especially in the early phase. We suggest that
exogenous lysozyme could be used as an adjuvant thera-
peutic agent for treating OM; however, further studies are
necessary to test this hypothesis.
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